Authors' response, part I: Observational studies analyzed like randomized experiments: Best of both worlds

Epidemiology

Volumn 19, Issue 6, 2008, Pages 789-792

  Herná, Miguel A ^a   Robins, James M ^b  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ESTROGEN; GESTAGEN; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; EVIDENCE BASED PRACTICE; HAZARD RATIO; HORMONAL THERAPY; HUMAN; INCIDENCE; INTENTION TO TREAT; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; NONRESPONSE BIAS; OBSERVATIONAL STUDY; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 64049085259     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e318188e85f     Document Type: Review

References (16)

1. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
2. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35-44.
3. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766-779.
4. Prentice R. Data analysis methods and the reliability of analytic epide-miologic research. Epidemiology. 2008; 19:785-788.
5. Hoover RN. The Sound and the Fury: Was It All Worth It? Epidemiology. 2008; 19:780-782.
6. Stampfer MJ. ITT for observational data - worst of both worlds? Epidemiology. 2008; 19:783-784.
7. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease - why renew the focus on the early years of Menopause? Am J Epidemiol. 2007;166:511-517.
8. Prentice RL, Pettinger M, Anderson GL. Statistical issues arising in the Women's Health Initiative. Biometrics. 2005;61:922-930.
9. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645-650.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
11. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004; 15:615-625.
12. Flanders WD, Klein M. Properties of 2 counterfactual effect definitions of a point exposure [Erratum in: Epidemiology 2008;19:168]. Epidemiology. 2007; 18:453-460.
13. Robins JM. A new approach to causal inference in mortality studies with sustained exposure periods - Application to control of the healthy worker survivor effect. Mathematical Modelling.1986;7:1393-1512. [Errata in Computers and Mathematics with Applications 1987;14:923- 945. Addendum in Computers and Mathematics with Applications 1987;14:923-. Errata to addendum in Computers and Mathematics with Applications. 1987;18:477].
14. Robins JM, Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, et al. eds. Advances in Longitudinal Data Analysis. New York: Chapman and Hall/CRC Press; 2009.
15. van der Laan MJ, Petersen ML, Joffe MM. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens, Int J Biostat. 2005; 1 article 4. (Electronic article). Available at: http://www.be-press.com/ijb/vol l/issl/4.
16. Robins JM, Hernán MA, Rotnitzky A. Invited commentary: effect modification by time-varying covariates. Am J Epidemiol. 2007;166: 994-1002.